Literature DB >> 25431270

Cystic fibrosis bone disease: is the CFTR corrector C18 an option for therapy?

Frédéric Velard1, Martial Delion1, Flora Lemaire1, Olivier Tabary2, Christine Guillaume1, Françoise Le Pimpec Barthès3, Lhousseine Touqui4, Sophie Gangloff1, Isabelle Sermet-Gaudelus5, Jacky Jacquot6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25431270     DOI： 10.1183/09031936.00174014

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  4 in total

Review 1.  Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies.

Authors:  J Jacquot; M Delion; S Gangloff; J Braux; F Velard
Journal:  Osteoporos Int       Date:  2015-10-02       Impact factor: 4.507

2.  The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis.

Authors:  Melissa S Putman; Logan B Greenblatt; Michael Bruce; Taisha Joseph; Hang Lee; Gregory Sawicki; Ahmet Uluer; Leonard Sicilian; Isabel Neuringer; Catherine M Gordon; Mary L Bouxsein; Joel S Finkelstein
Journal:  J Clin Endocrinol Metab       Date:  2021-03-08       Impact factor: 5.958

3.  miR-636: A Newly-Identified Actor for the Regulation of Pulmonary Inflammation in Cystic Fibrosis.

Authors:  Pauline Bardin; Tobias Foussignière; Nathalie Rousselet; Carine Rebeyrol; Joanna C Porter; Harriet Corvol; Olivier Tabary
Journal:  Front Immunol       Date:  2019-11-15       Impact factor: 7.561

4.  Treatment of cystic fibrosis related bone disease.

Authors:  Jagdeesh Ullal; Katherine Kutney; Kristen M Williams; David R Weber
Journal:  J Clin Transl Endocrinol       Date:  2021-12-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.